LeMaitre Vascular Dividend and Recent Developments: Insights Ahead of Ex-Dividend Date Aug 21, 2025
Generado por agente de IAAinvest Dividend Digest
domingo, 17 de agosto de 2025, 7:04 pm ET1 min de lectura
LMAT--
LeMaitre Vascular (LMAT) has announced a dividend of $0.200 per share, with an ex-dividend date set for Aug 21, 2025, and payment scheduled for Sep 4, 2025. This figure is significantly higher than the average of the last ten dividends, which stood at approximately $0.078 per share. The dividend type, translated from Chinese, is a cash dividend. The company last distributed dividends on May 29, 2025, maintaining the same per-share payout and dividend type.
Recently, LeMaitre VascularLMAT-- has seen notable transactions and updates that could influence its market performance. Director Lawrence Jasinski sold 976 shares at $92.78 each on Aug 12, 2025, a transaction valued at $90,553. This move highlights insider trading activity, which might affect investor sentiment.
Over the past week, LeMaitre Vascular reported second-quarter earnings, revealing a 15% revenue growth to $64.230 million and a gross margin of 70%, driven by international expansion and a premium product mix. The EMEA region registered a 23% sales growth, with the APAC region following with a 12% increase, fueled by demand for vascular care and new product approvals. Analysts project 2025 revenue of $251 million and an EPS of $2.30, reflecting confidence in the company's scalable global model.
As of late, Cetera Investment Advisers acquired 5,769 shares, indicative of growing interest in LMAT’s stock. Furthermore, LMATLMAT-- has been upgraded to 'Outperform' by analysts, reinforcing its position as a strong player in the medical device industry, known for its commitment to innovation and operational discipline.
In conclusion, LeMaitre Vascular is positioned as a compelling investment opportunity with its strategic expansions and promising financial health. Investors should note that Aug 21, 2025, is the last day to purchase LMAT shares to be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend distribution.
Recently, LeMaitre VascularLMAT-- has seen notable transactions and updates that could influence its market performance. Director Lawrence Jasinski sold 976 shares at $92.78 each on Aug 12, 2025, a transaction valued at $90,553. This move highlights insider trading activity, which might affect investor sentiment.
Over the past week, LeMaitre Vascular reported second-quarter earnings, revealing a 15% revenue growth to $64.230 million and a gross margin of 70%, driven by international expansion and a premium product mix. The EMEA region registered a 23% sales growth, with the APAC region following with a 12% increase, fueled by demand for vascular care and new product approvals. Analysts project 2025 revenue of $251 million and an EPS of $2.30, reflecting confidence in the company's scalable global model.
As of late, Cetera Investment Advisers acquired 5,769 shares, indicative of growing interest in LMAT’s stock. Furthermore, LMATLMAT-- has been upgraded to 'Outperform' by analysts, reinforcing its position as a strong player in the medical device industry, known for its commitment to innovation and operational discipline.
In conclusion, LeMaitre Vascular is positioned as a compelling investment opportunity with its strategic expansions and promising financial health. Investors should note that Aug 21, 2025, is the last day to purchase LMAT shares to be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend distribution.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios